Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;93(1):197-198.
doi: 10.1002/jmv.26317. Epub 2020 Jul 27.

COVID-19: What type of cytokine storm are we dealing with?

Guillaume Monneret  1   2 , Ihsane Benlyamani  2 , Morgane Gossez  1   2 , Jesus F Bermejo-Martin  3   4 , Marta Martín-Fernandez  3   4 , Pierre Sesques  5 , Florent Wallet  6 , Fabienne Venet  1   2
Affiliations
Comment

COVID-19: What type of cytokine storm are we dealing with?

Guillaume Monneret et al. J Med Virol. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Median/mean IL‐6 values in COVID‐19, septic shock, and cytokine release syndrome (CRS). Black horizontal lines depict medians for each group. CRS refers to cytokine release syndrome after CAR‐T cell infusion (at peaks of cytokine release). Values from recent/illustrative studies. COVID‐19 studies: Chen G et al. J Clin Invest. 2020;130:2620‐2629; Mo P et al. Clin Infect Dis. 2020 (Online); Zhou F. Lancet. 2020;395:1054‐1062; Zhu. Int J Infect Dis. 2020;95:332‐339; Monneret G et al. Intensive Care Med. 2020 (Online); Cai Q et al. Allergy. 2020; Gao Y et al. J Med Virol. 2020;92:791‐796; Qin C et al. Clin Infect Dis. 2020 (Online); Wang C et al. Intensive Care Med. 2020 (Online); Chen R et al. J Allergy Clin Immunol. 2020 (Online). CRS studies: Maude SL et al. N Engl J Med. 2014;371:1507‐1517; Lee DW et al. Blood. 2014;124:188‐195; Xu J et al. Proc Natl Acad Sci USA. 2019;116:9543‐9551; Teachey DT et al. Cancer Discov. 2016;6:664‐679; Hay KA et al. Blood. 2017;130:2295‐2306. Septic shock studies: Feng M et al. J Clin Lab Anal. 2016;30:1037‐1043; Song J et al. BMC Infect Dis. 2019;19:968; Tsalik EL et al. J Emerg Med. 2012;43:97‐106; Lin WC et al. PLoS One. 2017;12:e0178387; Ríos‐Toro JJ et al PLoS One. 2017;12:e0175254. Differences between groups were as follows: all groups (P < .0002, ANOVA), COVID‐19 vs septic shock (P < .002, Mann‐Whitney), COVID‐19 vs CRS (P < .002, Mann‐Whitney). ANOVA, analysis of variance; COVID, coronavirus disease; IL, interleukin‐6
See this image and copyright information in PMC

Comment on

References

    1. Andrianopoulos I, Papathanasiou A, Papathanakos G, Chaidos A, Koulouras V. Tocilizumab's efficacy in COVID‐19 patients is determined by the presence of cytokine storm [published online ahead of print June 22, 2020]. J Med Virol. 2020. 10.1002/jmv.26209 - DOI - PMC - PubMed
    1. Morena V, Milazzo L, Oreni L, et al. Off‐label use of tocilizumab for the treatment of SARS‐CoV‐2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36‐42. - PMC - PubMed
    1. Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID‐19‐induced cytokine release syndrome: a cautionary case report. Chest. 2020;158:e‐15‐e‐19. - PMC - PubMed
    1. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID‐19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695. - PMC - PubMed
    1. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID‐19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020;129:104444. - PMC - PubMed

Substances